vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Alector, Inc. (ALEC). Click either name above to swap in a different company.

Alector, Inc. is the larger business by last-quarter revenue ($6.2M vs $1.7M, roughly 3.8× Arcellx, Inc.). Alector, Inc. runs the higher net margin — -597.5% vs -3513.4%, a 2915.9% gap on every dollar of revenue. On growth, Alector, Inc. posted the faster year-over-year revenue change (-88.5% vs -89.2%). Over the past eight quarters, Alector, Inc.'s revenue compounded faster (-37.4% CAGR vs -79.5%).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for neurodegenerative diseases. Its product pipeline targets unmet medical needs including Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, and it collaborates with global pharmaceutical partners to advance candidate therapies through clinical trials.

ACLX vs ALEC — Head-to-Head

Bigger by revenue
ALEC
ALEC
3.8× larger
ALEC
$6.2M
$1.7M
ACLX
Growing faster (revenue YoY)
ALEC
ALEC
+0.7% gap
ALEC
-88.5%
-89.2%
ACLX
Higher net margin
ALEC
ALEC
2915.9% more per $
ALEC
-597.5%
-3513.4%
ACLX
Faster 2-yr revenue CAGR
ALEC
ALEC
Annualised
ALEC
-37.4%
-79.5%
ACLX

Income Statement — Q4 2025 vs Q4 2025

Metric
ACLX
ACLX
ALEC
ALEC
Revenue
$1.7M
$6.2M
Net Profit
$-58.1M
$-37.3M
Gross Margin
Operating Margin
-3850.2%
-634.4%
Net Margin
-3513.4%
-597.5%
Revenue YoY
-89.2%
-88.5%
Net Profit YoY
-23.4%
-1696.9%
EPS (diluted)
$-1.01
$-0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
ALEC
ALEC
Q4 25
$1.7M
$6.2M
Q3 25
$4.9M
$3.3M
Q2 25
$7.6M
$7.9M
Q1 25
$8.1M
$3.7M
Q4 24
$15.3M
$54.2M
Q3 24
$26.0M
$15.3M
Q2 24
$27.4M
$15.1M
Q1 24
$39.3M
$15.9M
Net Profit
ACLX
ACLX
ALEC
ALEC
Q4 25
$-58.1M
$-37.3M
Q3 25
$-55.8M
$-34.7M
Q2 25
$-52.8M
$-30.5M
Q1 25
$-62.3M
$-40.5M
Q4 24
$-47.1M
$-2.1M
Q3 24
$-25.9M
$-42.2M
Q2 24
$-27.2M
$-38.7M
Q1 24
$-7.2M
$-36.1M
Operating Margin
ACLX
ACLX
ALEC
ALEC
Q4 25
-3850.2%
-634.4%
Q3 25
-1248.3%
-1153.6%
Q2 25
-777.4%
-433.6%
Q1 25
-847.6%
-1216.5%
Q4 24
-348.2%
-13.4%
Q3 24
-129.1%
-315.7%
Q2 24
-127.8%
-302.4%
Q1 24
-40.3%
-275.0%
Net Margin
ACLX
ACLX
ALEC
ALEC
Q4 25
-3513.4%
-597.5%
Q3 25
-1127.1%
-1063.4%
Q2 25
-698.6%
-387.7%
Q1 25
-766.0%
-1101.6%
Q4 24
-308.4%
-3.8%
Q3 24
-99.4%
-275.2%
Q2 24
-99.3%
-256.4%
Q1 24
-18.3%
-227.0%
EPS (diluted)
ACLX
ACLX
ALEC
ALEC
Q4 25
$-1.01
$-0.34
Q3 25
$-0.99
$-0.34
Q2 25
$-0.94
$-0.30
Q1 25
$-1.13
$-0.41
Q4 24
$-0.87
$-0.02
Q3 24
$-0.48
$-0.43
Q2 24
$-0.51
$-0.40
Q1 24
$-0.14
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
ALEC
ALEC
Cash + ST InvestmentsLiquidity on hand
$450.3M
$256.0M
Total DebtLower is stronger
$10.0M
Stockholders' EquityBook value
$402.4M
$30.6M
Total Assets
$604.0M
$293.2M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
ALEC
ALEC
Q4 25
$450.3M
$256.0M
Q3 25
$461.4M
$291.1M
Q2 25
$453.1M
$307.3M
Q1 25
$543.3M
$354.6M
Q4 24
$587.4M
$413.4M
Q3 24
$574.3M
$457.2M
Q2 24
$516.7M
$503.3M
Q1 24
$573.9M
$562.1M
Total Debt
ACLX
ACLX
ALEC
ALEC
Q4 25
$10.0M
Q3 25
Q2 25
Q1 25
Q4 24
$10.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACLX
ACLX
ALEC
ALEC
Q4 25
$402.4M
$30.6M
Q3 25
$440.8M
$57.7M
Q2 25
$392.2M
$71.2M
Q1 25
$416.9M
$94.6M
Q4 24
$454.8M
$126.8M
Q3 24
$483.0M
$118.9M
Q2 24
$487.2M
$150.6M
Q1 24
$496.6M
$178.9M
Total Assets
ACLX
ACLX
ALEC
ALEC
Q4 25
$604.0M
$293.2M
Q3 25
$655.9M
$335.3M
Q2 25
$619.1M
$356.4M
Q1 25
$648.1M
$408.3M
Q4 24
$711.3M
$468.3M
Q3 24
$764.9M
$516.0M
Q2 24
$734.3M
$570.7M
Q1 24
$779.7M
$635.5M
Debt / Equity
ACLX
ACLX
ALEC
ALEC
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
0.08×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
ALEC
ALEC
Operating Cash FlowLast quarter
$-58.2M
$-41.7M
Free Cash FlowOCF − Capex
$-58.9M
FCF MarginFCF / Revenue
-3563.4%
Capex IntensityCapex / Revenue
46.2%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-212.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
ALEC
ALEC
Q4 25
$-58.2M
$-41.7M
Q3 25
$-49.2M
$-32.5M
Q2 25
$-39.7M
$-49.0M
Q1 25
$-63.1M
$-60.8M
Q4 24
$-46.0M
$-55.0M
Q3 24
$30.7M
$-50.7M
Q2 24
$-36.2M
$-62.8M
Q1 24
$-31.9M
$-61.3M
Free Cash Flow
ACLX
ACLX
ALEC
ALEC
Q4 25
$-58.9M
Q3 25
$-49.5M
$-32.5M
Q2 25
$-40.2M
$-49.1M
Q1 25
$-63.9M
$-60.8M
Q4 24
$-47.5M
$-55.2M
Q3 24
$28.4M
$-50.9M
Q2 24
$-39.5M
$-63.1M
Q1 24
$-38.3M
$-61.9M
FCF Margin
ACLX
ACLX
ALEC
ALEC
Q4 25
-3563.4%
Q3 25
-1000.3%
-997.6%
Q2 25
-532.4%
-623.0%
Q1 25
-786.4%
-1655.0%
Q4 24
-311.3%
-101.8%
Q3 24
109.2%
-332.1%
Q2 24
-144.1%
-418.6%
Q1 24
-97.7%
-389.3%
Capex Intensity
ACLX
ACLX
ALEC
ALEC
Q4 25
46.2%
0.0%
Q3 25
6.0%
0.3%
Q2 25
6.4%
0.1%
Q1 25
9.6%
0.5%
Q4 24
9.8%
0.3%
Q3 24
8.8%
1.4%
Q2 24
11.7%
2.2%
Q1 24
16.4%
3.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons